FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247282293> ?p ?o ?g. }

• W2247282293 abstract "13511 Background: Treatment until progression or planned interruption of first line chemotherapy is common in the therapy for metastatic colorectal cancer and are upon the discretion of the oncologist. A retrospective analysis was performed to determine the impact of these differing therapeutic strategies on overall survival. Methods: Eligible patients were treated between 2002 to 2004 in British Columbia. All patients received chemotherapy with both FOLFOX and FOLFIRI, either first or second line. Records were retrospectively reviewed for treatment interruption, efficacy and toxicity. Overall survival was the primary endpoint. Results: 101 patients were identified. Twenty-three patients who progressed before receiving 8 cycles of chemotherapy and 9 patients who stopped their chemotherapy due to toxicity were excluded. The remaining patients were analyzed for survival. Twenty-three patients were treated to progression of whom 6 received first line FOLFIRI and 17 received first line FOLFOX. The mean number of cycles of first line therapy was was 11.5. Forty six patients received a planned break. Of these, 21pateints received first line FOLFIRI and 25 patients received first line FOLFOX. Mean number of cycles of first line therapy was 9.7. Median survival of patients treated to progression was 16 months compared to 22 months for patients with planned break of therapy (p=0.003). The Hazard ratio was 2.3 (p=0.01) in favor of patients who had a planned break. Uni-variate and multivariate analysis showed no significance of sex, age, site (colon versus rectal), sequence and ECOG status as predictive factors. Conclusion: In this study, patients who were treated until progression with first line chemotherapy with either FOLFOX or FOLFIRI had an inferior survival. Possible explanations for the detrimental hazard ratio for patients treated to progression are decreasing reserve for second line therapy when first line therapy is prolonged and increasing resistance to 5-FU based therapy with prolonged exposure. As this is a retrospective, observational study, other variables not captured by the modeled covariates that may have influenced results. This data suggests that treating to best response and then allowing a break does not detrimentally affect survival. No significant financial relationships to disclose." @default.
• W2247282293 created "2016-06-24" @default.
• W2247282293 creator A5018856250 @default.
• W2247282293 creator A5038371805 @default.
• W2247282293 creator A5053138163 @default.
• W2247282293 creator A5062745925 @default.
• W2247282293 creator A5070331492 @default.
• W2247282293 creator A5083522110 @default.
• W2247282293 creator A5085412380 @default.
• W2247282293 creator A5087116862 @default.
• W2247282293 creator A5089913686 @default.
• W2247282293 date "2006-06-20" @default.
• W2247282293 modified "2023-09-23" @default.
• W2247282293 title "Metastatic Colorectal Cancer Treatment to progression or Not?" @default.
• W2247282293 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.13511" @default.
• W2247282293 hasPublicationYear "2006" @default.
• W2247282293 type Work @default.
• W2247282293 sameAs 2247282293 @default.
• W2247282293 citedByCount "0" @default.
• W2247282293 crossrefType "journal-article" @default.
• W2247282293 hasAuthorship W2247282293A5018856250 @default.
• W2247282293 hasAuthorship W2247282293A5038371805 @default.
• W2247282293 hasAuthorship W2247282293A5053138163 @default.
• W2247282293 hasAuthorship W2247282293A5062745925 @default.
• W2247282293 hasAuthorship W2247282293A5070331492 @default.
• W2247282293 hasAuthorship W2247282293A5083522110 @default.
• W2247282293 hasAuthorship W2247282293A5085412380 @default.
• W2247282293 hasAuthorship W2247282293A5087116862 @default.
• W2247282293 hasAuthorship W2247282293A5089913686 @default.
• W2247282293 hasConcept C121608353 @default.
• W2247282293 hasConcept C126322002 @default.
• W2247282293 hasConcept C143998085 @default.
• W2247282293 hasConcept C526805850 @default.
• W2247282293 hasConcept C71924100 @default.
• W2247282293 hasConceptScore W2247282293C121608353 @default.
• W2247282293 hasConceptScore W2247282293C126322002 @default.
• W2247282293 hasConceptScore W2247282293C143998085 @default.
• W2247282293 hasConceptScore W2247282293C526805850 @default.
• W2247282293 hasConceptScore W2247282293C71924100 @default.
• W2247282293 hasLocation W22472822931 @default.
• W2247282293 hasOpenAccess W2247282293 @default.
• W2247282293 hasPrimaryLocation W22472822931 @default.
• W2247282293 hasRelatedWork W132389072 @default.
• W2247282293 hasRelatedWork W1562954425 @default.
• W2247282293 hasRelatedWork W167317102 @default.
• W2247282293 hasRelatedWork W2069518285 @default.
• W2247282293 hasRelatedWork W2362472825 @default.
• W2247282293 hasRelatedWork W2411371100 @default.
• W2247282293 hasRelatedWork W2414419604 @default.
• W2247282293 hasRelatedWork W2591743724 @default.
• W2247282293 hasRelatedWork W3041570190 @default.
• W2247282293 hasRelatedWork W4255693185 @default.
• W2247282293 isParatext "false" @default.
• W2247282293 isRetracted "false" @default.
• W2247282293 magId "2247282293" @default.
• W2247282293 workType "article" @default.